---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-069414"
form_type: "8-K"
ticker: "AKTX"
cik: "0001541157"
company_name: "Akari Therapeutics Plc"
filed_at: "2024-06-05T23:59:59+00:00"
generated_at: "2026-06-01T06:15:31.283121+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Akari Therapeutics formalizes interim CEO compensation: $50k/month in equity, no cash/benefits/severance

## Summary
- Samir R. Patel appointed Interim President & CEO effective May 1; agreement signed May 31.
- Compensation entirely equity-based: $50,000/month in fully vested ordinary shares valued at monthly closing price.
- No annual bonus, employee benefits, or severance entitlements; at-will independent contractor role.
- Company may terminate agreement immediately for any reason.

## SEC filing metadata
- accession: 0000950170-24-069414
- form_type: 8-K
- ticker: AKTX
- cik: 0001541157
- company_name: Akari Therapeutics Plc
- filed_at: 2024-06-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1541157/000095017024069414/0000950170-24-069414-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1541157/000095017024069414/aktx-20240531.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-069414
- JSON: https://secwatch.observer/filing/0000950170-24-069414.json
- Plain text: https://secwatch.observer/filing/0000950170-24-069414.txt

## Key facts
- Executive change
  Samir R. Patel was appointed as Interim President and Chief Executive Officer at Akari Therapeutics Plc.
  - Action: appointed
  - Role: Interim President and Chief Executive Officer
  source text: As previously disclosed, on April 25, 2024, the board of directors (the “Board”) of Akari Therapeutics, Plc (the “Company”) appointed Samir R. Patel, M.D., a member of the Board, as Interim President and Chief Executive Officer, effective May 1, 2024, to serve in such capacities until such time as determined by the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1541157/000095017024069414/0000950170-24-069414-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.